Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

Inclusion Criteria:

Patients with LVEF =< 40% from treatment with anthracyclines for all malignancies at any dose at any time without evidence of other causes of cardiomyopathy
Documented New York Heart Association (NYHA) class I, II and III
Been treated with appropriate maximal medical therapy for heart failure
Able to perform 6 minute walk test
Patient or legally authorized representative able to sign informed consent
Patients with persistent LV dysfunction 90 days after discontinuation of trastuzumab

Exclusion Criteria:

Evidence of ischemic heart disease as determined by study cardiologist
Significant valvular disease; (aortic stenosis [AS] with aortic valve area [AVA] < 1.5 and severe aortic regurgitation [AR] and mitral regurgitation [MR])
History of familial cardiomyopathy
Recent documented myocarditis within 2 months of consent
History of infiltrative cardiomyopathy or restrictive cardiomyopathy
Epidermal growth factor receptor (eGFR) < 50 by Mayo or Cockcroft formula
Liver function tests > 3 x upper limit of normal
NYHA class IV heart failure
Inotropic dependence
Unstable or life-threatening arrhythmia
Coagulopathy international normalized ratio (INR) > 1.5
Mechanical or bioprosthetic heart valve
Cardiogenic shock
Breast feeding and/or pregnant women
Autoimmune disorders on current immunosuppressive therapy
Active infection not responding to appropriate therapy as determined by study chair
Trastuzumab treatment within the last 3 months